The case against Proteus-Otsuka's digital med. AliveCor's 6th CEO

Issue 012.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a doubly lucky 77 percent open rate. Here's what's happening this week:

Your editor has been waxing nostalgic on Twitter about digital health semantics (pre-2008 to present) with appearances from Golden Oldies like uHealth, wireless health and more.
Livongo went public this morning at $28 a share, higher than its already upgraded share price range. Health Catalyst also IPO'd today.
The American Telemedicine Association announced Partners HealthCare's Dr. Joseph Kvedar is its new president-elect.
FiercePharma pointed out that Pear Therapeutics' insomnia and depression DTx, Somryst, appears to be its first effort to go to market without its pharma partner Novartis. Will Pear go solo with that one?
Finally, STAT resurfaced the important issue of wearable device

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

The case against Proteus-Otsuka’s digital med. AliveCor’s 6th CEO

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

The case against Proteus-Otsuka’s digital med. AliveCor’s 6th CEO

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.